Výsledky vyhledávání - "Hazel Reynolds"

Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept

Autor: Arnold S. Freedman, Eric N. Jacobsen, Vassiliki A. Boussiotis, Jeffrey L. Kutok, Donna Neuberg, Agnieszka Szot, Annick D. Van den Abbeele, David E. Fisher, Jonathan W. Friedberg, Hazel Reynolds, Olivier Munoz

Publikováno v: Leukemia & Lymphoma. 49:902-909

Follicular dendritic cells (FDCs) support the survival of follicular lymphoma (FL). Tumor necrosis factor alpha (TNFalpha) is overexpressed by FL cells and is critical in the development and maintenance of FDCs. We hypothesised that TNFalpha might be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d2f55a982ddaa0cf438044a81bd087
https://doi.org/10.1080/10428190801950033

Zobrazit plný text záznamu

Plný text ve formátu HTML

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia

Autor: David C. Fisher, Bethany Tesar, Lillian Werner, Arnold S. Freedman, Evgeny Mikler, Christina Thompson, Jennifer R. Brown, Naoko Takebe, Lijian Yu, Donna Neuberg, Hazel Reynolds

Publikováno v: Leukemialymphoma. 56(12)

Obatoclax is a small molecule mimetic of the BH3 domain of BCL-2 family proteins. This phase 1 study combining obatoclax with FR was undertaken in chronic lymphocytic leukemia (CLL) patients relapsed after at least one prior therapy. Obatoclax was gi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a63336315b62273231118e2e2921823
https://pubmed.ncbi.nlm.nih.gov/25971907

Zobrazit plný text záznamu

Plný text ve formátu HTML

Ethical Issues in Cancer Genetics: 1) Whose Information Is It?

Autor: Andrea Farkas Patenaude, Jill Goldman, Karin M. Dent, Cate Walsh Vockley, Kelly Taylor, Meredith A. Keenan, Katherine A. Schneider, Anu Chittenden, Bonnie S. LeRoy, Judy Garber, Kelly J. Branda, Steven Joffe, Sonja Eubanks, Hazel Reynolds, Nancy Steinberg Warren

Publikováno v: Journal of Genetic Counseling. 15:491-503

This article presents and discusses four clinical cases that exemplify the complexity of ethical dilemmas concerning the provider's obligation to disclose or withhold genetic information from patients. Case 1: What is the responsibility of the cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33f8b705e17a171c6df5d226c4500f66
https://doi.org/10.1007/s10897-006-9053-4

Zobrazit plný text záznamu

A Phase I Study of Lenalidomide in Combination with Fludarabine and Rituximab in Previously Untreated CLL/SLL

Autor: Sean McDonough, Christina Thompson, Yanan Kuang, Jerome Ritz, Evgeny Mikler, Arnold S. Freedman, Hazel Reynolds, Donna Neuberg, Jennifer R. Brown, Ephraim P. Hochberg, Virginia Dalton, Lillian Werner, Jeremy S. Abramson

Lenalidomide is an immunomodulatory drug related to thalidomide that has recently been reported to have significant single agent activity in relapsed CLL, with response rates of 35-50% including some complete responses1,2. The mechanism of action is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::426dfc02b26dd0eeb59846e6dec4e05b
https://europepmc.org/articles/PMC3722583/

Zobrazit plný text záznamu

Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders

Autor: Hazel Reynolds, Megan Ash, David C. Fisher, Christina Thompson, Ann S. LaCasce, Jason B. Silverstein, Jennifer R. Brown, Arnold S. Freedman, Kimberly Phillips, Jennifer C. Clark, Donna Neuberg, Eric D. Jacobsen

Publikováno v: British journal of haematology. 143(3)

Increasing evidence points to a heritable contribution in the development of lymphoma. The goal of this study was to determine the rate of familial lymphoproliferative malignancy among consecutive lymphoma patients presenting to a tertiary care cente

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab60af788f703ceb98adb1751ab6e39
https://pubmed.ncbi.nlm.nih.gov/18729853

Zobrazit plný text záznamu

Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL

Autor: Evgeny Mikler, Christina Thompson, Hazel Reynolds, Naoko Takebe, Donna Neuberg, Bethany Tesar, David C. Fisher, Arnold S. Freedman, Jennifer R. Brown, Lillian Werner

Publikováno v: Blood. 118:2865-2865

Abstract 2865 Obatoclax is a small molecule mimetic of the BH3 domain of Bcl-2 family proteins. Obatoclax is broadly specific, with activity against Bcl-2, Bcl-X, Bcl-w and Mcl-1. CLL cells overexpress Bcl-2, Bcl-XL and Mcl-1 in particular, and obato

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd3320d99ca962882f12c769997c6b52
https://doi.org/10.1182/blood.v118.21.2865.2865

Zobrazit plný text záznamu

High Resolution Genomic Analysis In CLL Demonstrates Genomic Stability In Untreated Patients and Novel Markers of Progression In Treated Patients

Autor: Megan Hanna, Arnold S. Freedman, Jennifer R. Brown, Mick Correll, Yaoyu E. Wang, Donna Neuberg, Lillian Werner, Bethany Tesar, Hazel Reynolds, Stacey M. Fernandes, Laura E. MacConaill

Publikováno v: Blood. 116:2426-2426

Abstract 2426 Chronic lymphocytic leukemia is the most common leukemia of adults but still incurable. Prognosis at diagnosis is widely variable, and the key cytogenetic abnormalities determined by FISH remain one of the best predictors of prognosis a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ec7874cc32bd1425c98f92f65b5629a
https://doi.org/10.1182/blood.v116.21.2426.2426

Zobrazit plný text záznamu

A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL

Autor: Jennifer Romano, Donna Neuberg, Arnold S. Freedman, Jennifer R. Brown, Christina Thompson, Ephraim P. Hochberg, Jeremy S. Abramson, Jerome Ritz, Sean McDonough, Lillian Werner, Hazel Reynolds, Evgeny Mikler, Virginia Dalton

Publikováno v: Blood. 114:3426-3426

Abstract 3426 Poster Board III-314 Lenalidomide is an immunomodulatory drug recently reported to have an objective response rate (ORR) of 35-53% in relapsed/refractory CLL, even with poor risk features. Initial therapy of CLL currently includes chemo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0aa1c0308b12e9d943e7352b8abbd2af
https://doi.org/10.1182/blood.v114.22.3426.3426

Zobrazit plný text záznamu

Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma

Autor: Ann S. LaCasce, Hazel Reynolds, Jeffrey A. Barnes, David C. Fisher, Christiana E. Toomey, Ephraim P. Hochberg, Jeremy S. Abramson, Tak Takvorian, Eric D. Jacobsen, Philippe Armand

Publikováno v: Blood. 112:3595-3595

Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for nearly 3% of all newly diagnosed NHLs. Treatment of adult non-HIV-related BL with the intensive CODOX-M/IVAC regimen (modified Magrath regimen) produces com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3268a927405e7cc4bb7051a8c82f6c0c
https://doi.org/10.1182/blood.v112.11.3595.3595

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání